TITLE

Mutation predicted response to erlotinib in advanced NSCLC

PUB. DATE
October 2008
SOURCE
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p19
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses a study which reported the benefit of erlotinib for treating patients with non-small cell lung cancer if they had epidermal growth factor receptor mutations. Data from the study were presented by Rafael Rosell, chief of the medical oncology service at the Catalan Institute of Oncology, at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. The number of patients who participated in the study and the two mutations screened during the study are indicated.
ACCESSION #
34781540

 

Related Articles

  • Trial watch.  // Nature Reviews Cancer;Jun2009, Vol. 9 Issue 6, p386 

    The article presents research highlights from the field of cancer research. Rafael Rosell et al. deal with personalized drug treatments in the article "Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression." In their research article, Shuta Tomida...

  • O1–146RECHALLENGE WITH EGFR-TKI AFTER A DRUG HOLIDAY, RETROSPECTIVE STUDY IN SINGLE INSTITUTION. Kodani, M.; Igishi, T.; Sakamoto, T.; Touge, H.; Izumi, H.; Ito, S.; Kurai, J.; Yamaguchi, K.; Nakamoto, M.; Shimizu, E. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix44 

    No abstract available.

  • Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. Liang, Wenhua; Wu, Xuan; Fang, Wenfeng; Zhao, Yuanyuan; Yang, Yunpeng; Hu, Zhihuang; Xue, Cong; Zhang, Jing; Zhang, Jianwei; Ma, Yuxiang; Zhou, Ting; Yan, Yue; Hou, Xue; Qin, Tao; Dinglin, Xiaoxiao; Tian, Ying; Huang, Peiyu; Huang, Yan; Zhao, Hongyun; Zhang, Li // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs...

  • Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced nonsmall- cell lung cancer (OPTIMAL, CTONG-0802). Zhou, C.; Wu, Y. L.; Chen, G.; Feng, J.; Liu, X. -Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; Lu, S.; Zhang, L.; Hu, C.; Luo, Y.; Chen, L.; Ye, M.; Huang, J.; Zhi, X.; Zhang, Y.; Xiu, Q. // Annals of Oncology;Sep2015, Vol. 26 Issue 9, p1877 

    Background: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell...

  • Consequences of targeted treatments for second-line therapy. De Maio, E.; Tibaldi, C.; D'Incecco, A.; Bursi, S.; Barbara, C.; Cupini, S.; Di Marsico, R.; D'Arcangelo, M.; Landi, L.; Minuti, G.; Cappuzzo, F. // Annals of Oncology;Oct2010 Supplement 7, Vol. 21 Issue suppl_7, pvii234 

    The paradigm for first-line treatment of relapsed or metastatic non-small cell lung cancer (NSCLC) is changing. Large phase III trials demonstrated that, in 2010, we cannot select a therapy without an accurate definition of tumor histology and epidermal growth factor receptor (EGFR) status....

  • Erlotinib seals the deal in NSCLC treatment. Salmon, Kimberley // PharmacoEconomics & Outcomes News;10/20/2007, Issue 539, p3 

    Lung cancer is the leading cause of cancer-related death in many countries, and non-small cell lung cancer (NSCLC) is the predominant diagnosis. However, this disease can be difficult to treat, with many patients not presenting until the advanced stage, and therefore facing a poor prognosis....

  • Clinical and comparative utility of afatinib in non-small cell lung cancer. D'Arcangelo, Manolo; Hirsch, Fred R. // Biologics: Targets & Therapy;2014, Vol. 8, p183 

    The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. However, all patients...

  • Resistance to gefitinib. Uramoto, Hidetaka; Sugio, Kenji; Oyama, Tsunehiro; Sugaya, Masakazu; Hanagiri, Takeshi; Yasumoto, Kosei // International Journal of Clinical Oncology;Dec2006, Vol. 11 Issue 6, p487 

    Subsets of patients with non-small cell lung cancer (NSCLC) who carry somatic mutations in the epidermal growth factor receptor (EGFR) have responded remarkably well to a tyrosine kinase inhibitor (TKI), gefitinib. Despite the dramatic response to this inhibitor, most patients nevertheless...

  • Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Dearden, S.; Stevens, J.; Wu, Y.-L.; Blowers, D. // Annals of Oncology;Sep2013, Vol. 24 Issue 9, p2371 

    Background Meta-analyses were conducted to characterize patterns of mutation incidence in non small-cell lung cancer (NSCLC). Design Nine genes with the most complete published mutation coincidence data were evaluated. One meta-analysis generated a ‘mutMap’ to visually represent...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics